Table 1 Properties of selected anti-Aβ antibodies.
From: Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Clinical candidate | Mouse antibody analog | Clinical stage | Aβ selectivity (Monomer, Aggregate) | Epitope (residues) | Structure | Ref. |
|---|---|---|---|---|---|---|
aducanumab | chaducanumab | Ph3 | A ≫ M | 3–7 | yes | 8 and this work |
gantenerumab | chgantenerumab | Ph3 | A > M | 3–11, 18–27 | yes | |
BAN2401 | mAb158 | Ph2 | A ≫ M | 1–16 | no | |
NA | PFA1 | NA | A > M | 2–7 | yes | |
bapineuzumab | 3D6 | discontinued | A, M | 1–5 | yes | |
crenezumab | MABT5102A | Ph3 | A, M | 13–24 | yes | |
solanezumab | m266 | Ph3, partially halted | M ≫ A | 16–26 | yes | |
ponezumab | 2H6 | discontinued | M ≫ A | 30–40 | yes |
